Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is being done to evaluate the long-term safety of tegaserod in women with symptoms of dyspepsia who have completed the core study. Tegaserod will be evaluated at 6 mg twice daily.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tegaserod | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Long term safety at 6 months. |
| Measure | Description | Time Frame |
|---|---|---|
| Long term safety at 1 year. | ||
| Quality of life : Nepean Dyspepsia Index, WPAI, patient perception of study medication-dyspepsia questionaire. | ||
| Efficacy on satisfactory relief at month 6 and 12. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
- Early discontinuation from the double-blind study
Other protocol-defined inclusion/exclusion criteria may apply
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis | East Hanover NJ | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis | East Hanover | New Jersey | 07936-108 | United States |
Not provided
| ID | Term |
|---|---|
| D004415 | Dyspepsia |
| ID | Term |
|---|---|
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C105050 | tegaserod |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided